

FORM PTO-1390U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV. 5-93) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 5405 225 U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/830045
INTERNATIONAL APPLICATION NO. PCT/US99/24695	INTERNATIONAL FILING DATE 21 October 1999	PRIORITY DATE CLAIMED 22 October 1998
TITLE OF INVENTION Methods of Screening for Risk of Proliferative Disease and Methods for the Treatment of Proliferative Disease		
APPLICANT(S) FOR DO/EO/US Rose-Mary N. BOUSTANY; Wei-Xing GUO; Andrea AMALFITANO		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau (a courtesy copy is enclosed). c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. to 16. Below concern other document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> Copy of assignment document recorded in U.S. Prov. App. S/N _____ is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: International Preliminary Examination Report; International Search Report 		

U.S. APPLICATION NO. (If known, fill in) 09/830045		INTERNATIONAL APPLICATION NO. PCT/US99/24695		ATTORNEY'S DOCKET NUMBER 5405.225	
---	--	---	--	--------------------------------------	--



17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482). \$770.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4). \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$100.00				CALCULATIONS		PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$							
Claims	Number Filed	Number Extra	Rate				
Total Claims	47 -20 =	27	X \$18.00	\$486.00			
Independent Claims	6 -3 =	3	X \$80.00	\$240.00			
Multiple dependent claim(s) (if applicable)				+ \$270.00	\$		
TOTAL OF ABOVE CALCULATIONS =				\$826.00			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$413.00			
SUBTOTAL =				\$			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$413.00			
TOTAL NATIONAL FEE =				\$413.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$			
TOTAL FEES ENCLOSED =				\$413.00			
				Amount to be refunded	\$		
				charged	\$		

a. ☒ A check in the amount of \$413.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: Kenneth D. Sibley Myers Bigel Sibley & Sajovec P.A. PO Box 37428 Raleigh, NC 27627	"Express Mail" mailing label number <u>EL733093843US</u> Date of Deposit <u>April 20, 2001</u> I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to DO/EO/US, Commissioner for Patents, Washington, D.C. 20231  Vickie Diane Prior Date: <u>April 20, 2001</u>	 SIGNATURE 31,665 REGISTRATION NUMBER
--	--	---

5

METHODS OF SCREENING FOR RISK OF PROLIFERATIVE
DISEASE AND METHODS FOR THE
TREATMENT OF PROLIFERATIVE DISEASE

10 Rose-Mary N. Boustany, Wei-Xing Guo and Andrea Amalfitano

The present invention was made with Government support under grant RO1-NS30170 from the National Institutes of Health. The Government has certain rights to this invention.

15

Field of the Invention

The present invention involves methods of screening for risk of proliferative diseases such as cancer. The screening may be a diagnostic or prognostic screening. Methods of screening compounds for the treatment of proliferative diseases and
20 methods of treating proliferative disease are also disclosed.

Background of the Invention

The juvenile form of Batten disease is an autosomal recessive neurodegenerative disease of childhood (Boustany R-M, et al., *Am. J. Med. Genet. Suppl.* 5: 47-58 (1988)). It is clinically characterized by onset at age 5-6 years with
25 progressive blindness, generalized and myoclonic seizures, cognitive and motor decline and death in the mid to late twenties (Boustany R-M and Kolodny EH *Rev. Neurol. (Paris)* 145: 105-110 (1989); Boustany R-M *Am. J. Med. Genet.* 42: 533-535 (1992); Boustany R-M and Filipek P *J. Inher. Metab. Dis.* 16: 252-255 (1993)).

30 The CLN3 gene hypothesized to underly juvenile Batten disease encodes a 438 amino acid protein containing six putative hydrophobic transmembrane domains (The International Batten Disease Consortium *Cell* 82: 949-957 (1995); Janes RW et al., *FEBS Lett.* 399: 75-77 (1996)). It is expressed in a variety of human tissues

including brain. The CLN3 protein is highly conserved across species including dog, mouse, *Caenorhabditis elegans* and *Saccharomyces cerevisiae*: (Altshul SF, et al., *J. Mol. Biol.* **215**: 403-410 (1990); Mitchison HM, et al., *Genomics* **40**: 346-350 (1997)).

It has been debated whether the function of the intact CLN3 gene is
5 antiapoptotic, and that its integrity might be necessary for neuronal and photoreceptor survival. (See, e.g., Howard MK, et al., *J. Neurochem.* **60**: 1783-1791 (1993); Kulkarni GV and McCulloch CA *J. Cell Sci.* **107**: 1169-1179 (1994); Kulkarni GV and McCulloch CA *J. Cell Sci.* **107**: 1169-1179 (1994) Kulkarni GV and McCulloch CA *J. Cell Sci.* **107**: 1169-1179 (1994); Walker PR, et al., *Cancer Res.* **51**: 1078-1085
10 (1991); Bertand R, et al., *Exp. Cell Res.* **211**: 314-321 (1994); Stoll C, et al., *Cancer Res.* **36**: 2710-2713 (1976)). An antiapoptotic function for intact CLN3 is not generally accepted.

Summary of the Invention

15 As discussed in detail below, the present invention is based in part on the demonstration of antiapoptotic function for CLN3, on the surprising demonstration of upregulation of CLN3 in cancer cells, and on the finding that downregulation of CLN3 cancer cells inhibits the growth of cancer cells.

A first aspect of the present invention is a method of screening a subject for a
20 proliferative disease risk factor. The method comprises detecting the presence or absence of upregulation of the *CLN3* gene in the subject. The upregulation of the *CLN3* gene in the subject indicates the subject is at increased risk of developing a proliferative disease.

A second aspect of the present invention is a method of screening a compound
25 for efficacy in the treatment of a proliferative disease. The method comprises providing a group of subjects characterized by either (a) the presence of upregulation of the *CLN3* gene in the group or (b) the absence of upregulation of the *CLN3* gene in the group. The compound to be tested is then administered to the subjects, and the efficacy of the compound in the treatment of the proliferative disease is determined.

30 A third aspect of the present invention is an *in vitro* method of screening compounds for efficacy in treating a proliferative disease. The method comprises determining *in vitro* whether the compound inhibits the expression of the *CLN3* gene.

The inhibition of expression of the *CLN3* gene indicates the compound is useful in treating the proliferative disease.

A fourth aspect of the present invention is a method of screening compounds for efficacy in treating a proliferative disease. The method comprises determining *in vitro* whether said compound specifically binds to the *CLN3* gene product. The binding of the compound to the *CLN3* gene product indicates that the compound is useful in treating the proliferative disease.

A fifth aspect of the present invention is a method of inhibiting the growth of proliferative cells. The method comprises administering to the cells a vector containing and expressing a heterologous nucleic acid, wherein the heterologous encodes a product such as an antisense oligonucleotide that inhibits the expression of the *CLN3* gene in the cells.

A sixth aspect of the present invention is a recombinant vector useful for inhibiting the growth of proliferative cells. The vector contains and expresses in susceptible cells a heterologous nucleic acid, wherein said heterologous nucleic acid encodes a product that inhibits the expression of the *CLN3* gene in said cells.

The present invention is explained in greater detail in the drawings herein and the specification set forth below.

Brief Description of the Drawings

Figure 1. Overexpression of CLN3 enhances the rate of NT2 cell growth.

Figure 1A. Transient overexpression of CLN3: NT2 cells were transiently transfected with CLN3 subcloned into the pCMV4 vector by the calcium phosphate method. The left panel shows results of semi-quantitative RT-PCR analysis expressed as CLN3 mRNA levels relative to the internal control cyclophilin mRNA levels. NT2 cells transfected with 10 µg of CLN3 had a 4.5 times comparatively higher level of CLN3 mRNA than control cells. The right panel shows overexpression of CLN3 at the protein level as determined by immunostaining of NT2 cells with polyclonal anti-CLN3 antibody. Intense brown staining indicates higher levels of CLN3 protein in CLN3 overexpressing compared to control cells (scale bar 5 µm).

Figure 1B. Stable overexpression of CLN3: NT2 cells were stably transfected with CLN3 subcloned into the pOPRSV1CAT vector by the calcium phosphate

method. RT-PCR analysis shows the stably transfected NT2 cells to have a comparatively 2.5 times higher level of CLN3 mRNA (relative to cyclophilin) with respect to control cells (left panel). The right panel shows overexpression of CLN3 at the protein level as detected by immunostaining.

5 **Figure 1C.** Western blot analysis of CLN3 protein overexpression. Equal amounts of protein extracts from NT2 cells overexpressing CLN3 and appropriate controls were analyzed by immunoblotting with anti-CLN3 antibody. Cells were stably transfected with CLN3 subcloned either in the pOPRSV1CAT vector (lane 1) or the pCEP4 vector (lanes 3 and 4). The vector controls are shown in lane 2
10 (pOPRSV1CAT) and lane 5 (pCEP4). High levels of the CLN3 protein (~55kDa), indicated by the arrowhead, were observed in all three CLN3 overexpressing cell lines. Molecular weight markers, in kDa, are shown on the left.

Figure 1D. Effect of CLN3 overexpression on NT2 cell proliferation: [³H] thymidine was added to NT2 cells stably transfected with CLN3 either in the
15 pOPRSV1CAT vector (left panel) or the pCEP4 vector (right panel) at the indicated times and the incubation continued for another 4 hours. The incorporated [³H] thymidine is represented relative to that at 0 hour which is taken as 100%. Each data point is an average of three samples. The left panel shows results from one stable cell line overexpressing CLN3. The right panel shows results from two additional stable
20 cell lines overexpressing CLN3 (CLN3 I-pCEP4 and CLN3 II-pCEP4).

Figure 2. CLN3 protects from serum starvation induced growth inhibition.

Figure 2A. Serum deprivation results in inhibition of NT2 cell growth. The rate of growth of NT2 cells in the presence of serum (open square) or absence of serum (open circle) was compared by plating equal numbers of cells and counting at
25 6, 12, 18, 24 and 36 hours using the trypan blue method.

Figure 2B. CLN3 overexpression enhances the survival of NT2 cells following serum withdrawal. NT2 cells stably transfected with CLN3 or the vector (pOPRSV1CAT) alone were grown in serum free media for 12, 24 and 36 hours and their viability assessed by the trypan blue method. Results are expressed as cell
30 survival rate, which is the ratio of viable cells in serum free media to those in media with serum. Each point is an average of two experiments each of which was carried out in triplicate (p<0.05).

Figure 3. CLN3 rescues NT2 cells from drug induced apoptosis.

Figure 3A. CLN3 rescues from etoposide induced apoptosis: (i) For dose response curves, NT2 cells were treated with varying concentrations of etoposide and harvested at 6, 12, 18 and 24 h intervals. Viable cells were counted by the trypan blue method. Each data point is an average of three samples; (ii) NT2 cells that stably overexpress CLN3 were treated with etoposide (10 µg/ml) for 18h and the viable cells were counted by the trypan blue method. The bargrams show the survival rate (ratio of viable cells in drug treated to untreated samples) of drug treated NT2 cells overexpressing CLN3 compared to treated cells transfected with vector alone. Results are shown from three separate experiments, each carried out in triplicate.

Figure 3B. CLN3 rescues from vincristine induced apoptosis: (i) Dose response curve was determined by treating NT2 cells with varying concentrations of vincristine and counting the viable cells by the trypan blue method at various time intervals; (ii) NT2 cells stably transfected with CLN3 or vector alone were treated with vincristine (1 µg/ml for 18h) and the survival rate determined by viability assay using trypan blue. The result shown is for three separate experiments, each performed in triplicate. The bargram compares the survival rate of CLN3-overexpressing and control cells following treatment with vincristine.

Figure 3C. CLN3 rescues from staurosporine induced apoptosis: (i) Dose response curves for staurosporine in NT2 cells are shown. Viability was assessed at various time intervals by the trypan blue method; (ii) NT2 cells stably overexpressing CLN3 were treated with 500 nM staurosporine for 18h. Survival rate was determined by the trypan blue method and is shown for three separate experiments, each carried out in triplicate. The bargram compares the survival rate of CLN3 overexpressing and control cells following staurosporine treatment, and the table shows protection and degree of protection afforded by CLN3 overexpression.

Figure 4. CLN3 overexpressing NT2 cells show less DNA fragmentation than vector control NT2 cells in response to treatment with etoposide, staurosporine and vincristine. NT2 cells were transiently transfected with CLN3 (lanes 1, 3 and 5) or vector alone (lanes 2, 4 and 6) followed by treatment with either 10 µg/ml etoposide (lanes 1 and 2) or 500 nM staurosporine (lanes 3 and 4) or 1 µg/ml vincristine (lanes 5 and 6). Low molecular weight DNA was extracted and analyzed

on a 2% agarose gel in Tris-Borate-EDTA buffer (Rosenbaum et al, *Ann. Neurol.* 36, 864-870 (1994)).

Figure 5. CLN3 modulates ceramide formation.

Figure 5A. Overexpression of CLN3 lowers the level of endogenous ceramide in NT2 cells. NT2 cells were either transiently transfected with CLN3-CMV4 (left panel) or stably transfected with CLN3-OPRSV1CAT (right panel) and subjected to lipid extraction followed by measurement of ceramide. Each experiment was performed twice and in duplicate. The average percent drop in ceramide levels of NT2 cells overexpressing CLN3 compared to control cells is indicated within the bargraphs.

Figure 5B. CLN3 overexpression prevents activation of ceramide by vincristine. NT2 cells transiently (left panel) or stably (right panel) overexpressing CLN3 and the appropriate controls were all treated with vincristine (1 µg/ml) prior to ceramide quantitation. Absolute ceramide values were expressed as pmoles/nmoles phospholipid and are shown below. The change in ceramide level for each cell line following vincristine treatment was calculated as the percent change in ceramide between vincristine treated and untreated cells and plotted. Results are an average of two experiments.

Transient transfection	Untreated pmoles/nmoles phospholipid	Vincristine treated pmoles/nmoles phospholipid	% Change in ceramide Treated-untreated /untreated
CLN3-pCMV4	4.62 ± 0.34	5.45 ± 0.50	+ 18.0%
pCMV4	4.68 ± 0.4	5.92 ± 0.46	+ 25.5%
Stable transfection			
CLN3-Poprsv1CAT	2.47 ± 0.13	2.03 ± 0.14	-17.8%
pOPRSV1CAT	13.6 ± 0.04	20 ± 0.1	+ 47.0%

Figure 5C. Ceramide causes apoptosis in NT2 cells. Equal numbers of NT2 cells were plated and treated with increasing concentrations of C₂-ceramide. Cells were counted by the trypan blue method at 6, 12, 18 and 24 hour intervals. Each data point is an average of three samples.

Figure 5D. CLN3 does not protect NT2 cells from ceramide induced apoptosis. NT2 cells transiently transfected with CLN3 were treated with 5 µM of

either C₂- or C₆-ceramide for 18 hours. Cells were then harvested and viability assessed by the trypan blue method. The data represents averages of three separate experiments (p>0.2).

Figure 6. CLN3 protects PARP from proteolysis in NT2 cells. NT2 cells were transiently transfected with CLN3 or pCMV4 and treated with etoposide (10 µg/ml) for 18 hours. Total protein was harvested from cells and analyzed for proteolysis of PARP from 116 kDa to the 85 kDa fragment by Western blotting using a polyclonal anti-PARP antibody. Lanes 1 and 3 are transfected with pCMV4, lanes 2 and 4 are transfected with CLN3-pCMV4, and lanes 3 and 4 are treated with etoposide.

Figure 7. Proposed role for CLN3 in positive regulation of cell growth. CLN3 acts upstream of ceramide and may regulate one of a number of enzymes implicated in ceramide metabolism such as: acid or neutral sphingomyelinase (1), ceramidase (2), ceramide synthase (3), cerebroside synthase (4), and ceramide kinase (5).

Figure 8. Leukemia cell line HL-60 shows an overexpression of CLN3 compared to the transformed lymphoma cell line HS.

Figure 8A. Column graph shows results of quantitative RT-PCR analysis expressed as arbitrary units of CLN3 overexpression. HL-60 cells had 2.3 times higher level of CLN3 mRNA compared to HS cells.

Figure 8B. 10 µl each of HS and HL-60 cDNA, synthesized from the RT reaction, was hybridized with α³²P-dCTP in the PCR reaction. The amplified DNAs were separated on 8% polyacrylamide gels and visualized by autoradiography. Autoradiogram shows the amplified 289 bp fragment of CLN3 and 85 bp fragment of cyclophilin (the internal control) for each cell line. The amplified signal was quantitated on a Molecular Dynamics phosphorimager using ImageQuant software.

Figure 9. Both the breast cancer cell line BT-20 and the colon cancer cell line HCT-116 show an overexpression of CLN3 compared to the control 293, a kidney epithelial cell line. Column graph shows results of quantitative RT-PCR analysis expressed as arbitrary units of CLN3 overexpression. CLN3 mRNA levels were 2.8 and 4.1 times more in BT-20 and HCT-116, respectively, than in the control.

Figure 10. The breast cancer cell lines BT-20, BT-474, and BT-549 all show an overexpression of CLN3 compared to the control 293, a kidney epithelial cell line. Column graph shows results of quantitative RT-PCR analysis expressed as arbitrary units of CLN3 overexpression. BT-474, BT-20, and BT-549 had 1.9, 3.0, and 4.8
5 times more CLN3 expression than the control, respectively.

Figure 11. The colon cancer cell lines HCT-116, SW480, and SW1116 all show an overexpression of CLN3 compared to the control 293, a kidney epithelial cell line. Column graph shows results of quantitative RT-PCR analysis expressed as arbitrary units of CLN3 overexpression. HCT-116 and SW480 had 3.0 and 7.7 times
10 more CLN3 expression than the control, respectively. SW1116 had a dramatic 21.5 times the CLN3 mRNA level than did the control.

Figure 12. Comparison of the CLN3 mRNA expression in two melanoma cell lines, C32 and A-375, neuroblastoma cell line IMR-32, glioma cell line Hs683, and glioblastoma cell line A-172 to the control 293, a kidney epithelial cell line. Column
15 graph shows results of quantitative RT-PCR analysis expressed as arbitrary units of CLN3 overexpression. C32 actually had less CLN3 expressed, at 0.8 times, than did the control. Both A-375 and A-172 had a slight overexpression of CLN3, with 1.2 times more than the control. Hs683 had 1.7 times the CLN3 expression compared to the control. IMR-32 had a notable 12.7 times the CLN3 expression compared to the
20 control.

Figure 13 shows the inhibition of growth of SW1116 colon cancer cells one day after infection with a CLN3 antisense vector.

Figure 14 shows the inhibition growth of SW1116 cells one day after infection with a CLN3 antisense vector.

Figure 15 shows the inhibition of growth of SW1116 at various times after infection with a CLN3 antisense vector.
25

Figure 16 shows the inhibition of growth of BT-20 breast cancer cells one day after infection with a CLN3 antisense vector.

Figure 17 shows the cell growth curve of BT-20 cells at various times after infection with a CLN3 antisense vector.
30

Figure 18 shows the inhibition of growth of BT-20 cells at various times after infection with a CLN3 antisense vector.

Detailed Description of Preferred Embodiments

Amino acid sequences disclosed herein are presented in the amino to carboxy direction, from left to right. The amino and carboxy groups are not presented in the sequence. Nucleotide sequences are presented herein by single strand only, in the 5' to 3' direction.

The production of cloned genes, recombinant DNA, recombinant vectors, proteins and protein fragments by genetic engineering is well known, and can be carried out in accordance with known techniques. See, e.g., U.S. Patent No. 5,585,269 to Earp et al.; U.S. Patent No. 5,468,634 to Liu; and U.S. Patent No. 5,629,407 to Xiong et al. (the disclosures of all United States Patent references cited herein are to be incorporated herein by reference in their entirety).

The *CLN3* gene referred to herein is known, and is also referred to as the Batten Disease gene. See, e.g., The International Batten Disease Consortium, Isolation of a Novel Gene Underlying Batten Disease, *CLN3*, Cell, **82**, 949-957 (1995). The gene may be of any species depending upon the subject and/or the particular use thereof, but is typically mammalian and preferably human.

The term "risk factor" as used herein indicates subjects that possess the indicated trait or factor face an increased risk of developing the corresponding gene than subjects who do not possess the risk factor.

The term "upregulation" as used herein with respect to the *CLN3* gene means greater levels of the gene product are produced as compared to corresponding normal subjects.

The term "treat" as used herein refers to any type of treatment that imparts a clinical improvement in the condition of the patient, or delays the progression of the disease.

The term "proliferative disease" as used herein refers to both cancer and non-cancer disease. Preferably the proliferative disease is one characterized by increased expression of the *CLN3* gene product in afflicted patients. Illustrative non-cancer diseases include inflammatory and/or immunoproliferative disorders such as arthritis, fibrosis, asthma and allergies. The invention can be used to screen for risk of and/or treat a variety of different types of cancer cells, particularly malignant (and preferably solid) tumors of epithelial or mesenchymal cells. Examples of cancers that can be screened for risk of and/or treated by the present invention include breast cancer,

melanoma, lung cancer, colon cancer, leukemia (a liquid or non-solid tumor), soft tissue and bone sarcomas, neuroendocrine tumors such as islet cell carcinoma or medullary carcinoma of the thyroid, squamous carcinomas (particularly of the head and neck), adenocarcinomas, etc. The treatment of breast cancer is a particularly preferred target for carrying out the present invention.

While the present invention is primarily concerned with the screening and treatment of human subjects, the invention may also be carried out on animal subjects such as dogs, cats, and horses for veterinary purposes.

1. Screening Applications.

As noted above, the present invention provides a method of screening a subject for a proliferative disease risk factor. The method comprises detecting the presence or absence of upregulation of the *CLN3* gene in the subject. The upregulation of the *CLN3* gene in the subject indicates the subject is at increased risk of developing a proliferative disease. Thus, the presence of the risk factor is determined from the upregulation of the *CLN3* gene in the subject.

The method can be carried out whether or not the subject has been previously diagnosed as being afflicted with a proliferative disease, and whether or not the subject has been previously prognosed to be at risk of developing the proliferative disease.

The step of detecting whether the *CLN3* gene is upregulated (that is, the gene product thereof is found at increased levels as compared to normal subjects), can be carried out by any suitable means. For example, the step may be carried out by detecting increased mRNA levels for the *CLN3* gene in cells of the subject, or by detecting increased levels of the protein product of the *CLN3* gene in cells of the subject.

When the subject has previously been diagnosed as afflicted with a proliferative disease, the method may be carried out to monitor the progression of that disease, or monitor the efficacy of drug treatments that the patient has undergone for the treatment of that disease. Decreased levels of expression of the *CLN3* gene would be indicative of efficacy of the drug treatment.

As also noted above, the present invention also provides a method of screening a compound for efficacy in the treatment of a proliferative disease. The

method comprises providing a group of subjects characterized by either (a) the presence of upregulation of the *CLN3* gene in the group or (b) the absence of upregulation of the *CLN3* gene in the group. The compound to be tested is then administered to the subjects, and the efficacy of the compound in the treatment of the proliferative disease is determined. It will be appreciated that not every member of the group need possess the desired trait, as long as a sufficient number in the group possess the desired trait so that the typical effect of the presence or absence of the trait in the group can be discerned. By incorporating this information into a drug trial, whether the upregulation of the *CLN3* is present or absent in the group (or the group is divided into subgroups of those in whom upregulation is present and those in whom upregulation is absent) more accurate information can be obtained on the treatment of particular patients. It will be appreciated that it can be equally valuable to determine that a particular drug is efficacious for a particular patient population as it is to determine that a particular drug is not efficacious for a particular patient population, as the latter information can at least be useful in directing therapy to more promising treatments.

In vitro methods of screening compounds for efficacy in treating a proliferative disease are also disclosed herein. In general, in one embodiment, such methods comprise determining *in vitro* whether the compound inhibits the expression of the *CLN3* gene (preferably the mammalian gene, and most preferably the human gene). The inhibition of expression of the *CLN3* gene indicates the compound is useful in treating the proliferative disease. Numerous such methods are available. The methods can be carried out in a cell or cells, or can be carried out in essentially cell free preparation. The method can be carried out by screening for compounds that specifically disrupt either transcription or translation of the *CLN3* gene. The compound to be screened may be a member of a library of compounds (the term "compound" as used in this respect referring to both small organic compounds and other therapeutic agents such as recombinant viral vectors). The method may be carried out as a single assay, or may be implemented in the form of a high throughput screen in accordance with a variety of known techniques.

In another embodiment, the method of screening compounds for efficacy in treating a proliferative disease comprises determining *in vitro* whether said compound specifically binds to the *CLN3* gene product (preferably the mammalian gene product;

The present invention can be used with probe molecules, or libraries (where groups of different probe molecules are employed), of any type. In general, such probe molecules are organic compounds, including but not limited to that may be used to carry out the present include oligomers, non-oligomers, or combinations thereof. Non-oligomers include a wide variety of organic molecules, such as heterocyclics,

aromatics, alicyclics, aliphatics and combinations thereof, comprising steroids, antibiotics, enzyme inhibitors, ligands, hormones, drugs, alkaloids, opioids, benzodiazepenes, terpenes, porphyrins, toxins, catalysts, as well as combinations thereof. Oligomers include peptides (that is, oligopeptides) and proteins, 5 oligonucleotides (the term oligonucleotide also referred to simply as "nucleotide, herein) such as DNA and RNA, oligosaccharides, polylipids, polyesters, polyamides, polyurethanes, polyureas, polyethers, poly (phosphorus derivatives) such as phosphates, phosphonates, phosphoramides, phosphonamides, phosphites, phosphinamides, etc., poly (sulfur derivatives) such as sulfones, sulfonates, sulfites, 10 sulfonamides, sulfenamides, etc., where for the phosphorous and sulfur derivatives the indicated heteroatom for the most part will be bonded to C, H, N, O or S, and combinations thereof. Numerous methods of synthesizing or applying such probe molecules on solid supports (where the probe molecule may be either covalently or non-covalently bound to the solid support) are known, and such probe molecules can 15 be made in accordance with procedures known to those skilled in the art. *See, e.g.*, U.S. Patent No. 5,565,324 to Still et al., U.S. Patent No. 5,284,514 to Ellman et al., U.S. Patent No. 5,445,934 to Fodor et al. (the disclosures of all United States patents cited herein are to be incorporated herein by reference in their entirety).

Test compounds used to carry out the present invention may be of any type, including both oligomers or non-oligomers of the types described above in connection with probe molecules above. Again, such test compounds are known and can be prepared in accordance with known techniques.

Where multiple different probe molecules are desired to be tested, a screening substrate useful for the high throughput screening of molecular interactions, such as in “chip-based” and “pin-based” combinatorial chemistry techniques, can be prepared in accordance with known techniques. All can be prepared in accordance with known techniques. *See, e.g.*, U.S. Patent No. 5,445,934 to Fodor et al., U.S. Patent No. 5,288,514 to Ellman, and U.S. Patent No. 5,624,711 to Sundberg et al.

In the alternative, screening of libraries of probe molecules may be carried out with mixtures of solid supports as used in “split-pool” combinatorial chemistry techniques. Such mixtures can be prepared in accordance with procedures known in the art, and tag components can be added to the discreet solid supports in accordance with procedures known in the art. *See, e.g.*, U.S. Patent No. 5,565,324 to Still et al.

2. Vectors and Administration.

Vectors used to carry out the present invention are, in general, RNA virus or DNA virus vectors, such as lentivirus vectors, papovavirus vectors (e.g., SV40 vectors and polyoma vectors), adenovirus vectors and adeno-associated virus vectors. See generally T. Friedmann, *Science* **244**, 1275-16 (June 1989).

Examples of lentivirus vectors that may be used to carry out the present invention include Moloney Murine Leukemia Virus vectors, such as those described in U.S. Patent No. 5,707,865 to Kohn.

Any adenovirus vector can be used to carry out the present invention. See, e.g., U.S. Patent No. 5,518,913, U.S. Patent No. 5,670,488, U.S. Patent No. 5,589,377; U.S. Patent No. 5,616,326; U.S. Patent No. 5,436,146; and U.S. Patent No. 5,585,362. The adenovirus can be modified to alter or broaden the natural tropism thereof, as described in S. Woo, *Adenovirus redirected*, Nature Biotechnology **14**, 1538 (Nov. 1996).

15 Any adeno-associated virus vector (or AAV vector) can also be used to carry out the present invention. *See, e.g.*, U.S. Patent No. 5,681,731; U.S. Patent No. 5,677,158; U.S. Patent No. 5,658,776; U.S. Patent No. 5,658,776; U.S. Patent No. 5,622,856; U.S. Patent No. 5,604,090; U.S. Patent No. 5,589,377; U.S. Patent No. 5,587,308; U.S. Patent No. 5,474,935; U.S. Patent No. 5,436,146; U.S. Patent No. 20 5,354,678; U.S. Patent No. 5,252,479; U.S. Patent No. 5,173,414; U.S. Patent No. 5,139,941; and U.S. Patent No. 4,797,368.

The regulatory sequences, or the transcriptional and translational control sequences, in the vectors can be of any suitable source, so long as they effect expression of the heterologous nucleic acid in the target cells. For example, commonly used promoters are the LacZ promoter, and promoters derived from polyoma, Adenovirus 2, and Simian virus 40 (SV40). See, e.g., U.S. Patent No. 4,599,308.

The heterologous nucleic acid may encode any product that inhibits the expression of the *CLN3* gene in cells infected by the vector, such as an antisense oligonucleotide that specifically binds to the *CLN3* mRNA to disrupt or inhibit translation thereof, a ribozyme that specifically binds to the *CLN3* mRNA to disrupt or inhibit translation thereof, or a triplex nucleic acid that specifically binds to the *CLN3* duplex DNA and disrupts or inhibits transcription thereof. All of these may be

- carried out in accordance with known techniques, as (for example) described in U.S. Patents Nos. 5,650,316; 5,176,996, or 5,650,316 for triplex compounds, in U.S. Patents Nos. 5,811,537; 5,801,154; and 5,734,039 for antisense compounds, and in U.S. Patents Nos. 5,817,635; 5,811,300; 5,773,260; 5,766,942; 5,747,335; and 5,646,020 for ribozymes (the disclosures of which are incorporated by reference herein in their entirety). The length of the heterologous nucleic acid is not critical so long as the intended function is achieved, but the heterologous nucleic acid is typically from 5, 8, 10 or 20 nucleic acids in length up to 100, 200, 500 or 1000 nucleic acids in length, up to a length equal the full length of the *CLN3* gene.
- Once prepared, the recombinant vector can be reproduced by (a) propagating the vector in a cell culture, the cell culture comprising cells that permit the growth and reproduction of the vector therein; and then (b) collecting the recombinant vector from the cell culture, all in accordance with known techniques. The viral vectors collected from the culture may be separated from the culture medium in accordance with known techniques, and combined with a suitable pharmaceutical carrier for administration to a subject. Such pharmaceutical carriers include, but are not limited to, sterile pyrogen-free water or sterile pyrogen-free saline solution. If desired, the vectors may be packaged in liposomes for administration, in accordance with known techniques.
- Any suitable route of administration can be used to carry out the present invention, depending upon the particular condition being treated. Suitable routes include, but are not limited to, intravenous, intrarterial, intrathecal, intraperitoneal, intramuscular, and intralesional injection. Intralesional injection is currently preferred.
- The dosage of the recombinant vector administered will depend upon factors such as the particular disorder, the particular vector chosen, the formulation of the vector, the condition of the patient, the route of administration, etc., and can be optimized for specific situations. In general, the dosage is from about 10^7 , 10^8 , or 10^9 to about 10^{11} , 10^{12} , or 10^{13} plaque forming units (pfu).
- In addition to their pharmaceutical or veterinary use, the recombinant vectors of the present invention (sometimes also referred to as "active agents" herein) are useful *in vitro* to distinguish cells in culture based on their response to the active

agents, to induce apoptosis, etc. Such techniques are useful for both carrying out cell culture procedures and for drug screening purposes.

The present invention is described in further detail in the following non-limiting Examples. Abbreviations used herein are as follows: JNCL, juvenile neuronal ceroid lipofuscinosis; NT2, Ntera2/D1; NGF, nerve growth factor; ICE, interleukin-1 converting enzyme; PARP, poly (ADP-ribose) polymerase; RT-PCR, reverse transcription - polymerase chain reaction; PBS, phosphate buffered saline; DAB, 3, 3'-diaminobenzidine; TUNEL, Tdt mediated dUTP nick end labeling. Drs. Terry Lerner and Jim Gusella graciously provided the CLN3 cDNA.

10

EXAMPLE 1

CLN3 Defines a Novel Antiapoptotic Pathway

Operative in Neurodegeneration and Mediated by Ceramide

This example establishes a direct link between apoptosis and neurodegeneration in Batten disease at a molecular level.

I. EXPERIMENTAL PROCEDURES

Transfections: NT2 cells (ATCC# CRL1973) were plated on 60 mm dishes at a density of 0.5×10^6 and grown at 37°C in a 5% CO₂ atmosphere in DMEM supplemented with 10% fetal bovine serum and 100 units each of penicillin and streptomycin. The CLN3 cDNA was subcloned in the pCMV4 vector for transient transfections and in the pOPRSV1CAT vector or the pCEP4 vector (Invitrogen, Carlsbad, CA) for stable transfections (Andersson S, et al., *J. Biol. Chem.* **264**: 8222-8229 (1989); Fieck A, et al., *Nucleic Acid Res.* **20**: 1785-1791 (1992)). Transfections with the CLN3-pCMV4 construct or the CLN3-pOPRSV1CAT construct were carried out by the calcium phosphate method according to the manufacturer's protocol using the MBS transfection kit (Stratagene, LaJolla, CA). Transfections with the CLN3-pCEP4 construct were carried out using Superfect reagent (Qiagen, Valencia, CA) according to the manufacturer's method. Transiently transfected cells were harvested for all analyses within 48 hours of transfection. Stable clones were selected either with 500 µg/ml geneticin (CLN3-pOPRSV1CAT) or with 100 µg/ml hygromycin (CLN3-pCEP4) and subsequently grown under selective pressure.

Drug treatments: Dose response curves were established for etoposide, vincristine and staurosporine in NT2 cells (Figs.3Ai, 3Bi and 3Ci). Stably transfected NT2 cells and vector control cells were seeded at a density of 5×10^4 cells/well in 12-well plates, allowed to attach and then were treated with etoposide (10 $\mu\text{g/ml}$) or vincristine (1 $\mu\text{g/ml}$) or staurosporine (500 nM) for 18 h and the number of viable cells counted by the trypan blue assay. Survival represents the number of drug treated viable cells divided by the number of untreated viable cells and expressed as a percentage. Protection is calculated as the difference in survival between CLN3-overexpressing cells and the vector-transfected control cells. The degree of protection is calculated as the difference in survival between treated CLN3-overexpressing and vector control cells divided by the survival of treated vector control cells. The values are from three separate experiments, each of which was carried out in triplicate (Figs. 3Aii, 3Bii, and 3Cii).

RT-PCR: Messenger RNA was isolated from NT2 cells by the oligo-dT-cellulose method using the QuickPrep Micro mRNA Purification kit (Pharmacia Fine Chemicals, Piscataway, NJ). The mRNA was converted to cDNA by the reverse transcription (RT) reaction (Estus et al, 94). PCR reactions were set up with the first strand cDNA, 1U of Taq polymerase and 5 μCi of $\alpha^{32}\text{P}$ -dCTP in each reaction. The reactions were performed in Taq buffer containing 1.5 mM MgCl_2 , 2.5 mM dCTP and 5 mM each of dATP, dGTP and dTTP. The primers used for amplification of CLN3 were 5' primer: 5'-GGTGGACAGTATTCAAGGG-3' (958-976) and 3' primer: 5'-CTTGGCAGAAAGACGAAC-3' (1229-1246). Cyclophilin was used as the internal control and primers used for cyclophilin amplification were the 5' primer: 5'-AAATGCTGGACCCAACAC-3' (317-334) and 3' primer: 5'-AAACACCACATGCTTGCC-3' (384-401). The reaction conditions used were 1 minute at 94°C , 1 minute at 50°C and 2 minutes at 72°C for 20 cycles. The PCR amplified products were analyzed on an 8% non-denaturing polyacrylamide gel that was dried and visualized by autoradiography. The amplified signal was quantitated using a PhosphorImager (Molecular Dynamics Inc., Sunnyvale, CA). The results are expressed as the ratio of CLN3 signal to that of the internal control cyclophilin. This provides a reproducible and comparative, semi-quantitative measure of CLN3 expression.

Western Blotting for CLN3 and PARP detection: The CLN3 antibody used in this study is a polyclonal antibody raised against the peptide sequence AAHDILSHKRTSGNQSHVDP corresponding to amino acids 58-77 of the CLN3 protein (Research Genetics, Huntsville, AL). Total cellular extracts for CLN3
5 detection were prepared from NT2 cells transfected with CLN3 or the appropriate vector control. Cells were washed with cold PBS and lysed in buffer (250 mM NaCl, 0.1% NP40, 50 mM Hepes, pH 7.0, 5 mM EDTA, 1 mM DTT, 1 mM PMSF) on ice for 10 min. The lysate was collected and clarified by centrifugation at 12,000xg for 10 min at 4°C. The supernatant was quantitated for total protein by the BioRad
10 protein assay method. Equal amounts of total protein from each sample were electrophoresed on a 9% SDS-polyacrylamide gel in buffer containing 0.092 M glycine, 0.125 M Tris-OH and 2% SDS. The gel was transferred onto nitrocellulose membrane by semidry electroblotting and blocked by incubation in solution containing 3% BSA in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05%
15 Tween-20) buffer for one hour at 25°C followed by incubation with the CLN3 antibody (IgG fraction) diluted in TBST, for 15 hours at 25°C. After extensive washes with TBST buffer, the membrane was incubated in a 1:5000 dilution of goat-anti-rabbit IgG conjugated with horseradish peroxidase for 30 minutes at 25°C. The blot was washed and developed using the chemiluminescence detection system
20 (Amersham, Arlington Heights, IL).

For the PARP analysis, transfected NT2 cells were harvested by scraping in PBS followed by lysis in gel loading buffer containing 62.5 mM Tris-HCl pH 6.8, 6 M urea, 10% glycerol, 2% SDS, 0.003% bromophenol blue and 5% 2-
25 mercaptoethanol. The samples were incubated at 65°C for 15 min prior to being electrophoresed on a 9% SDS-polyacrylamide gel as above. The primary antibody for detection of PARP (obtained from Enzyme System, Dublin, CA) was used at a dilution of 1:5000. Western blotting was carried out as described above.

Immunocytochemistry and TUNEL Staining: For immunostaining, NT2 cells transfected with CLN3 or the vector alone were grown on glass coverslips, and fixed
30 in 2% formaldehyde and 0.2% glutaraldehyde for 15 minutes at 4°C. NT2 cells stably overexpressing CLN3 were also grown on coverslips and then fixed. The cells were permeabilized by treatment with 0.1% Triton X-100 for 30 minutes at 25°C followed

by incubation in 3% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 1 hour at 25°C. The cells were then incubated for 16 hours with the CLN3 antibody (IgG fraction) made up in PBS containing 3% BSA. After removal of the primary antibody and washes, the cells were incubated in a 1:500 dilution of biotin
5 conjugated goat-anti-rabbit IgG for 1 hour at 25°C. This was followed by incubation with avidin conjugated horseradish peroxidase for 30 minutes at 25°C. The cells were then washed and incubated with 3,3'-diaminobenzidine (DAB). The cells were counterstained with Hematoxylin Blue, rinsed in xylene and the coverslips mounted on slides. The slides were viewed with a light microscope. TUNEL staining was
10 carried out on transient- or stable-transfected NT2 cells grown on glass coverslips using the fluorescent Apoptag Direct kit (Oncor, Gaithersburg, MD) following the manufacturer's protocol (Schmitz G *Anal. Biochem.* 192: 222-231 (1991)). After counterstaining with propidium iodide, the coverslips were mounted on slides and the cells visualized under a fluorescent microscope.

15 *Cell proliferation assay by [³H] thymidine incorporation:* NT2 cells stably transfected with CLN3 or the appropriate vector control were plated in 12 well plates at a density of 1×10^5 cells/well and incubated with 0.5 μ Ci/ml [³H] thymidine at the indicated times for 4 h. The cells were then washed twice with ice-cold PBS and the DNA precipitated with 5% trichloroacetic acid. The TCA precipitate was dissolved in
20 0.4 ml of 0.25 M NaOH and the incorporated [³H] thymidine measured by liquid scintillation counting. For each time point three separate samples were measured.

Ceramide determination: NT2 cells transiently or stably transfected with CLN3 or the vector alone were harvested and the total lipid extracted according to the Bligh & Dyer method (Bligh EG and Dyer WJ *Can. J. Biochem. Physiol.* 37: 911-917
25 (1959)). The ceramide assay was performed as previously described (Zhang J, et al., *Proc. Natl. Acad. Sci. U.S.A.* 93: 5325-5328 (1996)). The labeled ceramide was viewed by autoradiography and quantitated using a liquid scintillation counter. Ceramide was expressed as pmole per nmole of total phospholipid. For measurement of activated ceramide, both the appropriate vector and CLN3-overexpressing cells
30 (transient and stable) were treated with vincristine (1 μ g/ml) for 18h and subjected to lipid extraction followed by ceramide measurements. The data from these

experiments is represented as change in ceramide level and reflects the percentage difference in ceramide values before and after vincristine treatment.

II. RESULTS AND DISCUSSION

A. Overexpression of CLN3 Increases NT2 Cell Survival

5 Transient overexpression of CLN3 subcloned into the pCMV4 vector in NT2 cells was assessed by RT-PCR as shown in the left panel of Fig. 1A. NT2 cells were stably transfected with CLN3 subcloned into pOPRSV1CAT, which resulted in a CLN3 signal 2.5 times stronger in CLN3 transfected NT2 cells compared to vector transfected cells as determined by RT-PCR (Fig. 1B, left panel). CLN3 protein
10 overexpression was demonstrated by Western blot and immunocytochemistry. The Western blot shows that CLN3 protein is expressed at a higher level in three stable NT2 cell clones (CLN3-pOPRSV1CAT seen in Fig.1D left panel, and CLN3 I-pCEP4 and CLN3 II-pCEP4 seen in Fig.1D left panel) overexpressing CLN3 in comparison to those transfected with vector alone (Fig. 1C). Immunocytochemistry confirms
15 CLN3 overexpression in both a transient overexpression system (Fig. 1A, right panel) and a stable overexpressing system (Fig.1B, right panel). Three different stable NT2 cell clones overexpressing CLN3 had a higher rate of thymidine incorporation compared to corresponding vector controls: for the CLN3-pOPRSV1CAT it was double, and for both pCEP4 clones it was five-fold at 36h compared to the vector
20 controls. This exceeded 100% at 36 hours for all three clones. This indicates that CLN3 positively modulates the rate of growth of NT2 cells.

B. CLN3 Rescues From Serum Withdrawal Induced Growth Inhibition

 Serum deprivation is known to induce apoptosis in lymphoid (Obeid LM, et al., *Science* 259: 1769-1771 (1993)), neuronal and other cell lines (Howard MK, et al.,
25 *J. Neurochem.* 60: 1783-1791 (1993); Kulkarni GV and McCulloch CA *J. Cell Sci.* 107: 1169-1179 (1994)). At the very least serum starvation inhibits growth. We demonstrate that serum starvation induces growth arrest in NT2 cells. NT2 cells grown in DMEM with 10% FBS exhibit logarithmic growth for 38 hours with a doubling time of 14 hours; serum withdrawal blunts logarithmic growth of NT2 cells
30 (Fig. 2A). The effect of stable CLN3 overexpression on growth inhibition induced by serum withdrawal was assessed using the trypan blue dye exclusion method. The survival rate was calculated as the number of viable cells grown in serum free

medium divided by the number of viable cells grown in serum supplemented medium. The amount of protection consisted of the difference between survival rate of CLN3- and vector-overexpressing NT2 cells. The degree of protection consists of the amount of protection divided by the survival rate of the vector control cells. CLN3 stably
5 transfected NT2 cells grown in medium lacking serum had a much higher survival rate as compared to NT2 cells stably transfected with vector alone. The degree of protection from serum starvation induced growth inhibition exceeded 100% in cells stably overexpressing CLN3 at 12 hours and was even higher at 36 hours (Fig 2B).

C. CLN3 Protects From Drug Mediated Apoptosis

10 The drugs etoposide and vincristine are chemotherapeutic agents known to induce apoptosis. The effect of etoposide is mediated by blocking topoisomerase II (Walker PR, et al., *Cancer Res.* 51: 1078-1085 (1991)), whereas vincristine induces cell death by interfering with spindle formation and the progression of the cell cycle (Harmon BV et al., *Cell Prolif.* 25: 523-536 (1992)). NT2 cells were stably
15 transfected with CLN3 or vector alone followed by treatment with 10 µg/ml of etoposide or 1 µg/ml of vincristine, which are the doses resulting in 50% killing at 18 hours (Figs. 3Ai and 3Bi). The protection conferred by stable CLN3 overexpression on NT2 cell viability was measured by trypan blue exclusion: CLN3-overexpressing NT2 cells had a degree of protection from cell death exceeding up to 78% following
20 treatment with etoposide (Fig. 3Aii). After vincristine treatment, stable CLN3-overexpressing NT2 cells had up to a 52% degree of protection as compared to vector transfected cells (Fig. 3Bii). Transiently transfected NT2 cells were harvested after 18 hours of drug treatment with etoposide, and stained by the TUNEL technique (data not shown). A much larger number of green apoptotic nuclei is seen in the treated
25 vector cells. Conversely, transient overexpression of antisense CLN3 cDNA decreased the survival rate of NT2 cells treated with etoposide by 10% and vincristine by 16%. Staurosporine, a potent protein kinase inhibitor, has been shown to trigger both the morphological changes and DNA fragmentation associated with apoptosis in many different cell lines (Bertand R, et al., *Exp. Cell Res.* 211: 314-321 (1994)). The
30 optimal staurosporine concentration for causing apoptosis in NT2 cells was established as being 500 nM (Fig. 3Ci). Viability was determined in NT2 cells stably transfected with CLN3 or vector following treatment with 500 nM staurosporine for

18 hours (Fig. 3Cii). The degree of protection of stable CLN3-overexpressing NT2 cell clones ranged from 42% to 129% compared to the corresponding vector-transfected NT2 cells.

A hallmark of apoptosis is the fragmentation of nuclear DNA into nucleosome-sized fragments creating a DNA ladder of 180 bp and its concatamers (Arends MJ, et al., *Am. J. Pathol.* 136: 593-608 (1990)). The drugs etoposide, staurosporine and vincristine cause DNA fragmentation in NT2 cells. NT2 cells were transiently transfected with CLN3 or vector alone, then treated with the drugs prior to the extraction of low molecular weight DNA (Rosenbaum DM, et al., *Ann. Neurol.* 36: 864-870 (1994)). Transient overexpression of CLN3 resulted in a reduction in the extent of DNA fragmentation caused by these drugs (Fig. 4). CLN3 was also found to be protective against vincristine and/or etoposide induced apoptosis in PC-12 neuronal cells, 293 kidney epithelial cells and U937 lymphoid cells. This was seen by either the TUNEL method or DNA ladder formation (results not shown).

15 D. The biologic function of CLN3

These findings assign a major biologic function to the novel gene CLN3 found to be defective in the juvenile form of Batten disease. When overexpressed, CLN3 protects cells from growth arrest induced by serum starvation and from death induced by treatment with the proapoptotic agents vincristine, etoposide and staurosporine.

20 The protective function of CLN3 appears to be vital for maintenance of cell survival in the central nervous system. The evidence for massive and progressive loss of neurons and photoreceptors in patients homozygous for the 1.02 kb CLN3 deletion provides a naturally occurring model where both alleles are knocked out. The neuropathologic lesion in the juvenile form of Batten disease underscores the

25 importance of the CLN3 protein for survival of both neurons and photoreceptor cells. However, we show that the antiapoptotic effect of CLN3 is not just restricted to neurons but is operative in other mammalian cells. We have confirmed it in pheochromocytoma derived PC-12 cells, epithelial 293 cells and lymphoid U937 cells. CLN3 seems to be crucial for the survival of postmitotic, fully differentiated

30 nondividing cells, particularly cortical neurons in the brain and photoreceptor cells in the eye. One possible explanation for this is that the eye and the brain are both immune-privileged sites that cannot tolerate destructive inflammatory responses: Fas-

Fas ligand interactions in the eye and brain promote apoptosis and normally protect these organs from tissue damage induced by inflammation (Griffith TS, et al., *Science* 270: 1189-1192 (1995); Griffith TS, et al., *Immunity* 5: 7-16 (1996)). Both neurons and photoreceptors are known to express Fas ligand and lymphoid cells express Fas receptor. This could be one of multiple mechanisms of immune privilege and the reason why loss of function of the antiapoptotic gene, CLN3, is phenotypically expressed only in the eye and brain in Batten disease. The absence or defects in key locations of the CLN3 gene in juvenile Batten may be sufficient for the apoptotic demise of both neurons and photoreceptors.

10 E. Modulation of endogenous ceramide by CLN3

Elevation of proapoptotic ceramide levels in the brain of patients with JNCL suggested a possible link between CLN3 and ceramide (Puranam K, et al., *Neuropediatrics* 28: 37-41 (1997)). We have shown that ceramide levels when measured as pmoles/nmoles of phospholipid drop by 18% in NT2 cells transiently transfected with CLN3 compared to NT2 cells just transfected with vector (Fig. 5A, left panel). Endogenous ceramide levels in NT2 cells stably transfected with CLN3 dropped by 69% (Fig. 5A, right panel). Also, both transient and stable overexpression of CLN3 prevented vincristine-induced activation of ceramide in NT2 cells (Fig. 5B). The attenuation of vincristine-induced activation of ceramide by CLN3 parallels the protective effect of CLN3 overexpression on NT2 cell survival seen following treatment with vincristine (Figs. 3Bii). We show that C₂-ceramide is an effective apoptotic agent in NT2 cells (Fig. 5C). Overexpression of CLN3 did not rescue NT2 cells from exogenous ceramide-induced killing (Fig. 5D). This suggests that CLN3 inhibits apoptosis proximally at the level of ceramide signaling in NT2 cells. The proteolytic cleavage of PARP or poly (ADP-ribose) polymerase by the protease caspase-3 has been identified as one of the key downstream events in the execution of apoptotic cell death (White E *Genes Develop.* 10: 1-15 (1996)). The chemotherapeutic drug etoposide has been shown to act via this pathway and cause proteolysis of the 116 kDa PARP protein to fragments that are 85 kDa and 25 kDa in size (Kaufmann S, et al., *Cancer Res.* 53: 3976-3985 (1993)). In order to investigate whether CLN3 protection is conferred along this pathway, we studied the effect of overexpression of CLN3 on the cleavage of PARP in NT2 cells. NT2 cells were

transiently transfected with CLN3 or vector alone and subsequently treated with 10 $\mu\text{g/ml}$ etoposide for 18 hours. Total cellular extracts were analyzed using a polyclonal anti-PARP antibody by Western blotting (Fig. 6). In the absence of etoposide, the 116 kDa PARP protein is intact in both CLN3 and vector transfected cells. Following etoposide treatment, NT2 cells transiently overexpressing CLN3 show a decrease in the amount of cleaved 85 kDa PARP fragment as compared to control cells. This indicates that CLN3 modulates ceramide levels which in turn lead to a blunting of the activation of the executionary phase of apoptosis by indirectly inhibiting activation of caspase-3, the enzyme that cleaves PARP into the apoptosis specific 85 kDa fragment.

F. Mechanism of action of CLN3 on cell survival

Without wishing to be bound to any particular theory for the instant invention, the following observations are offered. Antiapoptotic agents may protect the cell via one or more of the following: antioxidant effects; regulation of calcium transport; inhibition of the protease cascade; interference with protein translocation, ubiquitination or degradation; modulation of signal transduction pathways and/or regulation of release of mitochondrial cytochrome c oxidase (White E *Genes Develop.* 10: 1-15 (1996); Hannun YA *Science* 274: 1855-1859 (1996); Liu X, et al., *Cell* 86: 147-157 (1996)). The coexistence of elevation of proapoptotic ceramide and apoptosis in brain from patients with JNCL (Lane SC, et al., *J. Neurochem.* 67: 677-683 (1996); Puranam K, et al., *Neuropediatrics* 28: 37-41 (1997)) led us to suggest the following: the signaling lipid second messenger ceramide and the neuroprotective protein CLN3 partake in the same pathway of cell growth and regulation. Significant drops in endogenous and vincristine-activated ceramide levels in response to overexpression of the CLN3 protein in NT2 cells strongly supports this hypothesis. Ceramide formation or breakdown in the cell has at least five, if not more, known origins: 1) sphingomyelin hydrolysis via neutral or acid sphingomyelinase (Rena LA, et al., *Biochem. Pharm.* 53: 615-621 (1997)); 2) breakdown to sphingosine by ceramidase; 3) generation of cerebroside via cerebroside synthase, 4) de novo synthesis of ceramide by ceramide synthase, and 5) formation of ceramide phosphate by ceramide kinase. CLN3, predicted to reside in the membrane, probably fine-tunes regulation of the apoptotic pathway by blunting or attenuating ceramide generation.

CLN3 could be acting as a dimmer-switch for one of the reactions responsible for ceramide formation. One of these enzymes could be a target for the action of the CLN3 protein, or CLN3 could actually be one of those enzymes (Fig. 7). Ceramide leads to activation of caspase-3 (Smyth MJ, et al., *Biochem. J.* **316**: 25-28 (1996)).

5 We have also shown that the overexpression of CLN3 inhibits the activation of caspase-3 following etoposide treatment as demonstrated in Fig. 7. This occurs probably because CLN3 modulates endogenous ceramide levels further upstream and is most likely not a direct effect of CLN3 on caspase-3. The fact that CLN3 overexpression does not rescue NT2 cells from killing in response to exogenous C₂-
10 or C₆-ceramide confirms that CLN3 is acting upstream of ceramide in the apoptotic pathway. Once killing of cells has been set in motion by exogenously supplied ceramide, CLN3 is impotent in blocking cell death (Fig. 8). This is in contrast to Bcl-2, which acts downstream of ceramide, but upstream of caspase-3 (Perry DK, et al., *Cell Death Differen.* **4**: 29-33 (1997); Zhang J, et al., *Proc. Natl. Acad. Sci. U.S.A.* **93**:
15 5325-5328 (1996)). The upregulation of Bcl-2 in surviving neurons from brains of Batten patients actually implies the following: Bcl-2 and CLN3 protect neurons from apoptosis via two separate mechanisms that probably operate independently of one another (Puranam et al, *supra*). In our hands, PKC α is the predominant form of protein kinase C in NT2 cells. We found no effect of stable CLN3 overexpression on
20 translocation of PKC α in NT2 cells upon stimulation with phorbol esters (0.1 μ M PMA) even after 2 hours of stimulation (Lee JY, et al., *J. Biol. Chem.* **271**: 13169-13174 (1996)). Also, stable CLN3 overexpression had no effect on basal or calcium and lipid stimulated PKC kinase activity (unpublished data). This suggests that the effect of CLN3 on ceramide generation and ceramide-induced apoptosis in NT2 cells
25 is independent of PKC signal transduction pathways identifying an alternate route of sphingomyelin signal transduction.

EXAMPLE 2

CLN3 is Overexpressed in Cancer Cells

30 I. MATERIALS AND METHODS

Cell Culture. All cells used are human cell lines. The EB-virus transformed lymphoblast cell line, HS, was grown in suspension in RPMI 1640 media

supplemented with 10% fetal bovine serum (FBS). 293 (ATCC # CRL-1573), a kidney epithelial cell line, was grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS. The following cell lines were obtained from the American Type Culture Collection (Rockville, MD). HL-60 cells (ATCC #CCL-240) were grown in RPMI 1640 supplemented with 15% FBS. BT-20 cells (ATCC # HTB-19) were grown in RPMI 1640 supplemented with 5% FBS. BT-474 cells (ATCC # HTB-121) were grown in RPMI 1640 with Insulin and L-Glutamine supplemented with 10% FBS. BT-549 cells (ATCC # HTB-122) were grown in ROMI 1640 supplemented with 10% FBS. HCT-116 cells (ATCC # CCL-247) were grown in McCoy's 5A medium supplemented with 10% FBS. SW1116 (ATCC # CCL-233) and SW480 (ATCC # CCL-288) were both grown in Leibovitz's L-15 medium supplemented with 10% FBS. Hs 683 cells (ATCC # HTB-138), A-172 cells (ATCC # CRL-1620), and A-375 cells (ATCC # CRL-1619) were grown in DMEM supplemented with 10% FBS. IMR-32 cells (ATCC # CCL-127) and C32 cells (ATCC # 1585) were both grown in Eagle's Minimum Essential Medium with non-essential amino acids supplemented with 10% FBS.

All cell lines were supplemented with 100 units each of penicillin and streptomycin and maintained at 37°C in a 5% CO₂ atmosphere with the exception of SW1116, which required a free gas exchange environment of CO₂ and atmospheric air. Cells were fed 2-3 times/week.

Quantitative RT-PCR. RT-PCR was used to assess differences in CLN3 messenger RNA levels in cell lines. Approximately 2.5×10^5 cells were used per sample for the mRNA harvesting. The mRNA was isolated from each sample by the oligo-dT-cellulose method using the Quick Prep Micro mRNA Purification kit (Pharmacia Fine Chemicals, Piscataway, NJ). The mRNA was then converted to cDNA by the reverse transcription (RT) reaction in accordance with known techniques. For each sample, one-fourth of the RNA obtained, or 5 µl, was used for the RT reaction. The RT reaction was carried out in buffer containing 50 mM Tris-HCL, pH 8.3, 40 mM KCL, 6 mM MgCl₂, 1 mM DTT, 0.5 mM each of dATP, dCTP, dGTP and dTTP, 16 µM random primers (haxamers) and 20 U Rnasin (Promega Corp., Madison, WI) in a final volume of 30 µl. After addition of 1 U of Superscript reverse transcriptase (GIBCO BRL), the sample was incubated at 20°C for 10 minutes

followed by 50 minutes at 42°C. The reaction was terminated by adding 70 µl DEPC treated water and incubating at 94°C for 5 minutes. The PCR reactions were set up with 10 µl of the cDNA, synthesized in the RT reaction above, 1 U of Taq polymerase (Perkin Elmer), and 5 µCi of $\alpha^{32}\text{P}$ -dCTP in each reaction. The reactions were performed in Taq buffer (Perkin Elmer), containing 15. mM MgCl_2 , 2.5 mM dCTP and 5 mM each of dATP, dGTP, and dTTP. The primers use for amplification of CLN3 and cyclophilin, an internal control for mRNA, are listed below. The reaction conditions used for amplification were 1 minute at 94°C, 1 minute at 50°C, and 2 minutes at 72°C for 20 cycles in a 9600 Perkin Elmer Thermocycler (Foster City, CA). The PCR amplified products were analyzed on an 8% nondenaturing acrylamide gel, which as dried and visualized by autoradiography. The amplified signal was quantitated on a Molecular Dynamics phosphorimager using ImageQuant software (Sunnyvale, CA). The results are expressed as the ratio of CLN3 signal to that of the internal control, cyclophilin; the quantitated value of CLN3 present in the sample was divided by the quantitated value of cyclophilin.

Primers used for PCR amplification of human CLN3 were:

5' primer: 5'-GGTGGACAGTATTCAGGG-3' (958-976)

3' primer: 5'-CTTGGCAGAAAGACGAAC-3' (1229-1246)

Primers used for amplification of human cyclophilin amplification:

5' primer: 5'-AAATGCTGGACCCAACAC-3' (317-334)

3' primer: 5'-AAACACCCACATGCTTGCC-3' (384-401)

II. RESULTS.

An initial look at EB-virus transformed lymphoblasts (HS) and a leukemia cell line (HL-60) show that HL-60 cells had 2.3 times more CLN3 expression than HS after normalizing to the internal control, cyclophilin (Fig. 8A). Next, 293, a kidney epithelial cell line, was chosen as a control because a wide variety of cancer cell morphology is epithelial. To test its suitability and viability as a control, the level of CLN3 expressed in 293 was compared to the levels expressed in HCT-116, a colon cancer cell line, and BT-20, a breast cancer cell line. CLN3 levels were 4.1 and 2.8 times more in HCT-116 and BT-20, respectively, than in 293 (Fig. 9A).

Based on the elevated CLN3 expression of BT-20 compared to 293, two more breast cancer cell lines, BT-474 and BT-549, were selected for comparison with 293

along with BT-20. Results show that all three breast cancer cells have upregulated CLN3 mRNA levels compared to 293 (Fig. 10A). BT-474, BT-20, and BT-549 had 1.9, 3.0, and 4.8 times more CLN3 expression than 293, respectively. To better substantiate the elevated CLN3 expression in HCT-116, a well differentiated colon cancer cell line, SW480, and a poorly differentiated colon cancer cell line, SW1116, were chosen, along with HCT-116, for comparison with 293 (Fig. 11A). HCT-116 again showed over-expression of CLN3 compared to 293, with 3.0 times more CLN3 expressed. SW480 showed a more dramatic over-expression, with 7.7 times the level of 293. SW1116 had the largest difference in CLN3 expression compared to 293, with 21.5 times more CLN3 expressed.

A further screening of other cancer types was conducted. Two melanoma cell lines, C32 and A-375, a neuroblastoma cell line, IMR-32, a glioma cell line, Hs683, and a glioblastoma cell line, A-172, were compared against 293 (Fig. 12A). Interestingly, C32 (melanoma) actually showed 0.8 times the CLN3 expression compared to 293. It was the only cell line examined in this experiment that had less CLN3 expression than 293. The other melanoma cell line, A-375, and the glioblastoma cell line A-172, both had a very slight upregulation of CLN3, with 1.2 times more than 293. Hs683, the glioma cell line, had 1.7 times the CLN3 expression compared to 293. The neuroblastoma cell line, IMR-32, had a notable 12.7 times the CLN3 expression compared to 293.

EXAMPLE 3

Preparation of Adenoviral *CLN3* Antisense Vectors

A CMV enhancer/promoter element, juxtaposed to the CLN3 DNA in an antisense configuration, followed by the SV-40 polyadenylation signal was subcloned as a minigene cassette into the *AscI* site of the shuttling plasmid pAdAscLwt. PAdAscLwt contains as a circular plasmid : nucleotides 1-358 of the Ad5 genome, followed by the *AscI* restriction enzyme subcloning site, followed by nucleotides 3329-15671 of the Ad5 genome, followed by the bacterial plasmid backbone containing the ampicillin resistance gene and bacterial origin of replication derived from the commonly used bacterial plasmid pAT153. The resultant plasmid was designated pAdAscLwtCMV-antisenseCLN3pA. The shuttle plasmid was linearized

by restriction enzyme digestion, and cotransfected into human 293 cells (supplying adenoviral E1 functions in trans) along with ClaI restriction enzyme digested full length adenoviral DNA. Successful recombination between the homologous portions of the shuttle plasmid and the Ad viral DNA sequences resulted in the generation of a recombinant, E1 deleted Ad vector capable of transducing the CMV-driven antisense CLN3 cDNA to all cells amenable to Ad vector infection.

EXAMPLE 4

CLN3 Antisense Vectors Inhibit

Growth of Cancer Cells

Cell proliferation was assayed by counting cell numbers and measuring [³H]-thymidine incorporation. Data were expressed as the mean values of three wells.

To observe a dose-response relationship, BT-20 breast cancer cells and SW1116 colon cancer cells were plated overnight in 24-well plates at a density of 1×10^5 cells/well. Then, cells were infected with Ad-Antisense-CLN3 or adenovirus (vector) at 8, 40, and 80 MOI. After 24 hours, 0.5 μ Ci/ml [³H]thymidine (DuPont) was added to each well for 4 hours. To measure [³H]thymidine incorporation, each well was washed with two changes of ice-cold PBS. Thereafter, DNA was precipitated with 5% trichloroacetic acid and dissolved in 0.4 ml of 0.25 M NaOH. Incorporated radioactivity was detected by liquid scintillation counting. Data for SW1116 is given in **Figure 13**.

To study a time-response relationship, BT-20 and SW1116 cells were plated overnight in 12 well plates at a density of 2×10^5 cells/well. Then, cells were infected with Ad-Antisense-CLN3 or adenovirus (vector) at 10 MOI. At the indicated dates, cell proliferation was assayed by [³H]thymidine incorporation and/or by counting cells using a hemocytometer. Cell growth of SW1116 after one-day infection is given as thymidine uptake in **Figure 14** and as cell numbers at various days after infection in **Figure 15**. Cell growth of BT-20 cells after one-day infection is given in **Figure 16**, and as cell numbers at various days after infection in **Figure 17**. Finally, thymidine uptake of BT-20 cells at various days after infection is given in **Figure 18**.

These data indicate that the proliferation of cancer cells, specifically colon cancer cells and breast cancer cells, is inhibited by infection with a vector that expresses an antisense construct to the *CLN3* gene transcript.

5 The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

What is Claimed is:

1. A method of screening a subject for a proliferative disease risk factor,
comprising:
detecting the presence or absence of upregulation of the *CLN3* gene in said
5 subject;
the upregulation of the *CLN3* gene in said subject indicating said subject is at
increased risk of developing a proliferative disease.
2. The method of claim 1, wherein said subject has been previously diagnosed
10 as afflicted with said proliferative disease.
3. The method of claim 1, wherein said subject has not been previously
diagnosed as afflicted with said proliferative disease.
- 15 4. The method of claim 1, wherein said subject has been previously
prognosed to be at risk of developing said proliferative disease.
5. The method of claim 1, wherein said subject has not been previously
prognosed to be at risk of developing said proliferative disease.
20 6. The method of claim 1, wherein said detecting step is carried out by
detecting increased mRNA levels for said *CLN3* gene.
7. The method of claim 1, wherein said proliferative disease is cancer.
25 8. The method of claim 1, wherein said proliferative disease is breast cancer.
9. The method of claim 1, wherein said proliferative disease is colon cancer.
- 30 10. A method according to claim 1, wherein said patient has undergone
treatment for said proliferative disease.

11. A method of screening a compound for efficacy in the treatment of a proliferative disease, comprising:

providing a group of subjects characterized by either (a) the presence of upregulation of the *CLN3* gene in said group or (b) the absence of upregulation of the *CLN3* gene in said group;
administering said compound to said subjects; and then
determining the efficacy of said compound in the treatment of said proliferative disease.

12. A method according to claim 11, wherein said group of subjects is characterized by the presence of upregulation of the *CLN3* gene in said group.

13. A method according to claim 11, wherein said group of subjects is characterized by the absence of upregulation of the *CLN3* gene in said group.

14. A method according to claim 11, wherein said proliferative disease is cancer.

15. A method according to claim 11, wherein said proliferative disease is breast cancer.

16. A method according to claim 11, wherein said proliferative disease is colon cancer.

17. An *in vitro* method of screening compounds for efficacy in treating a proliferative disease, comprising:
determining *in vitro* whether said compound inhibits the expression of the *CLN3* gene;
the inhibition of expression of the *CLN3* gene indicating said compound is useful in treating said proliferative disease.

18. A method according to claim 17, wherein said determining step is carried out in a cell.

19. A method according to claim 17, wherein said determining step comprises determining whether said compound inhibits transcription of said *CLN3* gene.

5 20. A method according to claim 17, wherein said determining step comprises determining whether said compound inhibits translation of said *CLN3* gene.

21. A method according to claim 17, wherein said proliferative disease is characterized by the upregulation of the *CLN3* gene in subjects afflicted with said
10 proliferative disease.

22. A method according to claim 17, wherein said proliferative disease is cancer.

15 23. A method according to claim 17, wherein said proliferative disease is breast cancer.

24. A method according to claim 17, wherein said proliferative disease is colon cancer.

20 25. A method of inhibiting the growth of proliferative cells, comprising:
administering to said cells a vector containing and expressing a heterologous nucleic acid, wherein said heterologous nucleic acid encodes a product that inhibits the expression of the *CLN3* gene in said cells.

25 26. A method according to claim 25, wherein said cells are mammalian cells.

27. A method according to claim 25, wherein said vector is a viral vector.

30 28. A method according to claim 25, wherein said vector is an RNA virus vector.

29. A method according to claim 25, wherein said vector is a DNA virus vector.

30. A method according to claim 25, wherein said vector is an adenovirus vector.

31. A method according to claim 25, wherein said heterologous nucleic acid encodes an antisense oligonucleotide that binds to *CLN3* mRNA.

32. A method according to claim 25, wherein said heterologous nucleic acid encodes a ribozyme that degrades *CLN3* mRNA.

33. A recombinant vector useful for inhibiting the growth of proliferative cells, said vector containing and expressing in susceptible cells a heterologous nucleic acid, wherein said heterologous nucleic acid encodes a product that inhibits the expression of the *CLN3* gene in said cells.

34. A recombinant vector according to claim 33, wherein said susceptible cells are mammalian cells.

35. A recombinant vector according to claim 33, wherein said vector is a viral vector.

36. A recombinant vector according to claim 33, wherein said vector is an RNA virus vector.

37. A recombinant vector according to claim 33, wherein said vector is a DNA virus vector.

38. A recombinant vector according to claim 33, wherein said vector is an adenovirus vector.

- 35 -

39. A recombinant vector according to claim 33, wherein said heterologous nucleic acid encodes an antisense oligonucleotide that binds to *CLN3* mRNA.

40. A recombinant vector according to claim 33, wherein said heterologous
5 nucleic acid encodes a ribozyme that degrades *CLN3* mRNA.

41. A method of screening compounds for efficacy in treating a proliferative disease, comprising:
determining *in vitro* whether said compound specifically binds to the *CLN3*
10 gene product;
the binding of said compound to the *CLN3* gene product indicating said compound is useful in treating said proliferative disease.

42. A method according to claim 41, wherein said determining step is carried
15 out by split pool combinatorial chemistry.

43. A method according to claim 41, wherein said determining step is carried out by chip-based combinatorial chemistry.

20 44. A method according to claim 41, wherein said determining step is carried out by pin-based combinatorial chemistry.

45. A method according to claim 41, wherein said compound is an oligomeric compound.
25

46. A method according to claim 41, wherein said compound is a non-oligomeric compound.

30

CORRECTED
VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/23624 (43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/US99/24695 (22) International Filing Date: 21 October 1999 (21.10.99) (30) Priority Data: 60/105,262 22 October 1998 (22.10.98) US (71) Applicant (for all designated States except US): DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive, P.O. Box 90083, Durham, NC 27712 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): <u>BOUSTANY</u> , Rose-Mary, N. [US/US]; 103 Pinecrest Road, Durham, NC 27705 (US). <u>GUO</u> , Wei-Xing [CA/US]; 889 Louise Circle, Durham, NC 27705 (US). <u>AMALFITANO</u> , Andrea [US/US]; 3305 Middlebrook Court, Durham, NC 27705 (US). (74) Agents: SIBLEY, Kenneth, D. et al.; Myers, Bigel, Sibley, & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS OF SCREENING FOR RISK OF PROLIFERATIVE DISEASE AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASE (57) Abstract A method of screening a subject for a proliferative disease risk factor comprises detecting the presence or absence of upregulation of the <i>CLN3</i> gene in the subject. The upregulation of the <i>CLN3</i> gene in the subject indicates the subject is at increased risk of developing a proliferative disease. Methods of screening compounds for the treatment of proliferative diseases based on the <i>CLN3</i> gene and its product are also disclosed, along with methods of treating such diseases and vectors useful therefore.		

*(Referred to in PCT Gazette No. 38/2000, Section II)

1 / 18








FIG. 1A

2 / 18



CLN3



pOPRSV1
CAT




FIG. 1B

3 / 18




FIG. 1C

4 / 18




FIG. 1D

5 / 18




FIG. 2A




FIG. 2B

6 / 18




FIG. 3Ai




FIG. 3Aii




FIG. 3Bi




FIG. 3Bii

8 / 18




FIG. 3Ci




FIG. 3Cii




FIG. 4




FIG. 6

10/18




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 7




FIG. 9




FIG. 8




FIG. 11




FIG. 10




FIG. 12




FIG. 14




FIG. 13

17 / 18




FIG. 15




FIG. 16

18 / 18




FIG. 17




FIG. 18



09/830,045 012302

#6

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 5405.225

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHODS OF SCREENING FOR RISK OF PROLIFERATIVE DISEASE AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASE,**

the specification of which

☐ is attached hereto

OR

☒ was filed on **April 20, 2001** as United States Application No. **09/830,045** or PCT

International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56, including material information that became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

60/105,262	10/22/1998
Application Number(s)	Filing Date (MM/DD/YYYY)
Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below.

PCT/US99/24695	10/21/1999	Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. I also appoint the following registered attorney(s) to represent me before all competent International Authorities in connection with any and all international applications filed by me with an appropriate receiving office claiming priority to the U.S. application. I also appoint the following registered attorney(s) to make or receive payment on my behalf in connection with the filing of such international applications.

Customer Number:**20792**

PATENT TRADEMARK OFFICE

Send correspondence to:

Customer Number:**20792**

PATENT TRADEMARK OFFICE

Direct telephone calls to:

Kenneth D. Sibley
(919) 854-1400

Facsimile:

(919) 854-1401

Full name of first inventor:

Rose-Mary N. Boustany

Inventor's

Signature:

Date:

5/9/02

Residence:

Durham, North Carolina NC

Citizenship:

United States of America

Mailing Address:

103 Pinecreat Road
Durham, North Carolina 27705

2-00 Full name of second inventor:

Wei-Xing Guo

Inventor's
Signature:



Date: 05/06/2002

Residence:

Northridge, California *CA*

Citizenship:

Canada

Mailing Address:

167 Monterey Road, #F
South Pasadena, California 91030

300 Full name of third inventor:

Andrea Amalfitano

Inventor's

Signature: AA

Date: 5/10/02

Residence:

Durham, North Carolina NC

Citizenship:

United States of America

Mailing Address:

3305 Middlebrook Court
Durham, North Carolina 27705